HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 23,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/Space/Rocket%20launch%20by%20Alones%20via%20Shutterstock.jpg)
/Business%20process%20analysis%20and%20network%20connectivity%20by%20THAWEERAT%20via%20Adobe%20Stock.jpeg)